Skip Navigation

What we do

Our research aims to improve the access and targeting, and to assess the quality and safety of artemisinin-based combination therapy (ACT), the WHO recommended first-line treatment for malaria.

News from our Partners

In "On the road to test and treat—are we there yet?", Scott Wittet from MalariaCare at PATH highlights the importance of diagnosis and treatment in managing illnesses that cause fever.

Malaria research publications

Browse through more than 70 journal articles published by ACT Consortium investigators on the access, targeting, safety and quality of antimalarials.

Multimedia section

Watch videos, browse a prezi and listen to podcasts with ACT Consortium investigators talking about their studies on the access, targeting, quality and safety of ACT drugs.

View all ACT Consortium news

The ACT Consortium is an international research collaboration formed in November 2007 to answer key questions on malaria drug delivery in Africa and Asia.  

Our goal is to develop and evaluate delivery mechanisms to improve ACT access, targeting, safety and quality. 

The ACT Consortium is funded by the Bill & Melinda Gates Foundation and has partners throughout Africa, Asia, Europe and the United States.  It is coordinated through the London School of Hygiene & Tropical Medicine.